Trial Profile
A Phase 4, Open-label, Multicentre, 2-Year Safety Study of Lisdexamfetamine Dimesylate in Children and Adolescents Aged 6-17 Years with Attention-Deficit/Hyperactivity Disorder (ADHD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 25 Jul 2022
Price :
$35
*
At a glance
- Drugs Lisdexamfetamine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Shire; Shire Pharmaceutical Development
- 23 May 2018 Results (n=314) assessing longer-term effects of lisdexamfetamine dimesylate on weight, height, body mass index and pubertal development in children and adolescents with attention-deficit/hyperactivity disorder, were published in the CNS Drugs.
- 30 Jan 2018 Results assessing cognitive impairment using the cambridge neuropsychological test automated battery (CANTAB) published in the CNS Drugs
- 01 Sep 2015 Results presented at the 28th Annual Congress of the European College of Neuropsychopharmacology